keyword
https://read.qxmd.com/read/35324016/conjugated-detergent-micelles-as-a-platform-for-igm-purification
#21
JOURNAL ARTICLE
Gunasekaran Dhandapani, Ellen Wachtel, Ishita Das, Mordechai Sheves, Guy Patchornik
IgM antibodies hold promise as anticancer drugs and as agents for promoting immune homeostasis. This promise has not been realized due to low expression levels in mammalian cells producing IgM class antibodies, and the failure of protein A chromatography for IgM purification. Here we describe a non-chromatographic platform for quantitatively capturing IgM's at neutral pH which are then recovered with 86-94% yield and >95% purity at pH 3. The platform contains micelles conjugated with the [(bathophenanthroline)3 :Fe2+ ] amphiphilic complex...
March 24, 2022: Biotechnology and Bioengineering
https://read.qxmd.com/read/34980578/soho-state-of-the-art-updates-and-next-questions-waldenstr%C3%A3-m-macroglobulinemia-2021-update-on-management-and-future-directions
#22
REVIEW
Sheeba K Thomas
Waldenstrom macroglobulinemia (WM) is a low-grade B-cell lymphoproliferative disorder. It is defined by having ≥ 10% bone marrow infiltration with lymphoplasmacytic cells and/or an immunoglobulin M (IgM) monoclonal gammopathy of ≥3g/dL. Risk factors include a personal history of IgM MGUS, and a family history of WM or a related disorder. Race, sex, and chronic antigen stimulation also appear to influence risk. Between 93 to 97% of patients with WM have a somatic mutation of the MYD88 gene. Of these, approximately 30% also have a mutation of CXCR4...
June 2022: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/34913186/baseline-type-2-biomarker-levels-and-response-to-tezepelumab-in-severe-asthma
#23
RANDOMIZED CONTROLLED TRIAL
Jonathan Corren, Tuyet-Hang Pham, Esther Garcia Gil, Kinga Sałapa, Pin Ren, Jane R Parnes, Gene Colice, Janet M Griffiths
BACKGROUND: Tezepelumab is a human monoclonal antibody that blocks activity of thymic stromal lymphopoietin (TSLP). In the phase IIb PATHWAY study (NCT02054130), tezepelumab significantly reduced annualized asthma exacerbation rates (AAERs) versus placebo in adults with severe, uncontrolled asthma. We evaluated the effects of tezepelumab in reducing type 2 (T2) inflammatory biomarker levels in the PATHWAY population, and the relationship between baseline T2 biomarker levels and AAER. METHODS: Adults with severe, uncontrolled asthma (n = 550) were randomized to tezepelumab (70 mg or 210 mg every 4 weeks, or 280 mg every 2 weeks) or placebo for 52 weeks...
June 2022: Allergy
https://read.qxmd.com/read/34876373/impact-of-etiological-cytogenetic-abnormalities-on-the-depth-of-immunoparesis-and-survival-in-newly-diagnosed-multiple-myeloma
#24
JOURNAL ARTICLE
Jessica Caro, David Cairns, Tom Menzies, Eileen Boyle, Charlotte Pawlyn, Gordon Cook, Martin Kaiser, Brian A Walker, Roger Owen, Graham H Jackson, Gareth J Morgan, Jennifer Heaney, Mark T Drayson, Faith E Davies
INTRODUCTION/BACKGROUND: Immunoparesis, or low polyclonal immunoglobulin levels, is commonly seen in multiple myeloma (MM), and is associated with poor clinical outcomes. MM can be divided into subgroups with distinct biology and outcomes based on etiologic cytogenetic abnormalities. These include hyperdiploidy and translocations of t(11;14), t(4;14), t(14;16), and t(14;20), with the latter 3 associated with high-risk disease. We hypothesized that the different etiologic cytogenetic abnormalities drive bone marrow microenvironmental changes, resulting in different degrees of immunoparesis, and subgroup-dependent effects on clinical outcomes...
April 2022: Clinical Lymphoma, Myeloma & Leukemia
https://read.qxmd.com/read/34865422/-lymphoplasmacytic-lymphoma-a-clinicopathological-and-prognostic-analysis-of-27-cases
#25
JOURNAL ARTICLE
Y Chen, F Zhang, H M Wu, X L Luo, K P Zhang, Y H Liu
Objective: To study the clinical manifestations, pathologic features, diagnosis and differential diagnosis, treatment and prognosis of lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM). Methods: Twenty-seven cases of LPL from January 2016 to December 2020 at Guangdong Provincial People's Hospital were collected. The clinical data, histomorphology, immunophenotype, MYD88 L265P mutation, treatment and prognosis were analyzed retrospectively. Results: There were 19 males and 8 female patients, with median age of 63 years...
December 8, 2021: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
https://read.qxmd.com/read/34758192/semiquantitative-interpretation-of-anticardiolipin-and-anti%C3%AE-2glycoprotein-i-antibodies-measured-with-various-analytical-platforms-communication-from-the-isth-ssc-subcommittee-on-lupus-anticoagulant-antiphospholipid-antibodies
#26
JOURNAL ARTICLE
Arne Vandevelde, Walid Chayoua, Bas de Laat, Jean-Christophe Gris, Gary W Moore, Jacek Musiał, Stéphane Zuily, Denis Wahl, Katrien M J Devreese
BACKGROUND: Antiβ2glycoprotein I (aβ2GPI) and anticardiolipin (aCL) IgG/IgM show differences in positive/negative agreement and titers between solid phase platforms. Method-specific semiquantitative categorization of titers could improve and harmonize the interpretation across platforms. AIM: To evaluate the traditional 40/80-unit thresholds used for aCL and aβ2GPI for categorization into moderate/high positivity with different analytical systems, and to compare with alternative thresholds...
February 2022: Journal of Thrombosis and Haemostasis: JTH
https://read.qxmd.com/read/34703870/multiple-myeloma-detection-of-free-monoclonal-light-chains-by-modified-immunofixation-electrophoresis-with-antisera-against-free-light-chains
#27
JOURNAL ARTICLE
Dorian Wilhite, Ahmed Arfa, Thomas Cotter, Natasha M Savage, Roni J Bollag, Gurmukh Singh
Introduction: Neoplastic monoclonal gammopathies are frequently associated with production of excess free monoclonal light chains. A sensitive method for detecting free monoclonal light chains in serum could provide a marker for residual/minimal residual disease and as an adjunct to serum protein electrophoresis to serve as a screening method for monoclonal gammopathies. Methods: Conventional serum immunofixation electrophoresis was modified by applying undiluted serum samples, and staining for serum free light chains with antisera specific to free light chains...
November 2021: Practical Laboratory Medicine
https://read.qxmd.com/read/34604074/preclinical-characterization-of-gls-010-zimberelimab-a-novel-fully-human-anti-pd-1-therapeutic-monoclonal-antibody-for-cancer
#28
JOURNAL ARTICLE
Beilei Lou, Hua Wei, Fang Yang, Shicong Wang, Baotian Yang, Yong Zheng, Jiman Zhu, Shaoyu Yan
Background: Zimberelimab (GLS-010) is a novel fully human monoclonal immunoglobulin G4 (IgG4) against the programmed cell death-1 (PD-1) receptor. Aim: To evaluate the affinity, competitive blocking capability, T cell activation effect, cytotoxic effector functions by Fc, preliminary anti-tumor activity, and pharmacokinetics of GLS-010. Methods: The affinity of GLS-010 to PD-1 and the ability of GLS-010 to block the PD-L1/2 to PD-1 interaction on the cell surface were measured...
2021: Frontiers in Oncology
https://read.qxmd.com/read/34124325/immune-subtraction-for-improved-resolution-in-serum-protein-immunofixation-electrophoresis-and-antibody-isotype-determination-in-a-patient-with-autoantibody
#29
Asad Ullah, Nivin Omar, Natasha M Savage, Roni J Bollag, Gurmukh Singh
Heavy chain isotypes of low level monoclonal immunoglobulins are sometimes obscured in serum immunofixation electrophoresis (SIFE) by a heavy background of polyclonal immunoglobulins. However, accurate determination of the heavy chain isotype is essential for a complete diagnosis, as isotype determination of autoantibodies may have relevance in determining therapeutic procedures. Immune subtraction (IS) was employed in a patient with neuropathy and GD1a autoantibody. IS allowed identification of the cognate heavy chain related to a lambda light chain restriction noted on initial SIFE as well as isotype determination of the autoantibody...
August 2021: Practical Laboratory Medicine
https://read.qxmd.com/read/33974366/autologous-ex-vivo-lentiviral-gene-therapy-for-adenosine-deaminase-deficiency
#30
MULTICENTER STUDY
Donald B Kohn, Claire Booth, Kit L Shaw, Jinhua Xu-Bayford, Elizabeth Garabedian, Valentina Trevisan, Denise A Carbonaro-Sarracino, Kajal Soni, Dayna Terrazas, Katie Snell, Alan Ikeda, Diego Leon-Rico, Theodore B Moore, Karen F Buckland, Ami J Shah, Kimberly C Gilmour, Satiro De Oliveira, Christine Rivat, Gay M Crooks, Natalia Izotova, John Tse, Stuart Adams, Sally Shupien, Hilory Ricketts, Alejandra Davila, Chilenwa Uzowuru, Amalia Icreverzi, Provaboti Barman, Beatriz Campo Fernandez, Roger P Hollis, Maritess Coronel, Allen Yu, Krista M Chun, Christian E Casas, Ruixue Zhang, Serena Arduini, Frances Lynn, Mahesh Kudari, Andrea Spezzi, Marco Zahn, Rene Heimke, Ivan Labik, Roberta Parrott, Rebecca H Buckley, Lilith Reeves, Kenneth Cornetta, Robert Sokolic, Michael Hershfield, Manfred Schmidt, Fabio Candotti, Harry L Malech, Adrian J Thrasher, H Bobby Gaspar
BACKGROUND: Severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency (ADA-SCID) is a rare and life-threatening primary immunodeficiency. METHODS: We treated 50 patients with ADA-SCID (30 in the United States and 20 in the United Kingdom) with an investigational gene therapy composed of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with a self-inactivating lentiviral vector encoding human ADA . Data from the two U...
May 27, 2021: New England Journal of Medicine
https://read.qxmd.com/read/33926007/myd88-l265p-detection-in-igm-monoclonal-gammopathies-methodological-considerations-for-routine-implementation
#31
JOURNAL ARTICLE
Martina Ferrante, Daniela Furlan, Silvia Zibellini, Michela Borriero, Chiara Candido, Nora Sahnane, Silvia Uccella, Elisa Genuardi, Beatrice Alessandria, Benedetta Bianchi, Barbara Mora, Daniele Grimaldi, Irene Defrancesco, Cristina Jiménez, Federica Cavallo, Dario Ferrero, Irene Dogliotti, Michele Merli, Marzia Varettoni, Simone Ferrero, Daniela Drandi
In IgM monoclonal gammopathies MYD88L265P is a prognostic and predictive biomarker of therapy response. MYD88L265P detection is mainly performed by allele-specific quantitative PCR (ASqPCR), however recently, droplet digital PCR (ddPCR) has been proved to be suitable for MYD88L265P screening and minimal residual disease monitoring (MRD). This study compared ASqPCR and ddPCR to define the most sensitive method for MYD88L265P detection in bone marrow (BM), peripheral blood (PB) sorted or unsorted CD19+ cells, and in plasma cell-free DNA (cfDNA)...
April 26, 2021: Diagnostics
https://read.qxmd.com/read/33649747/therapeutic-activity-of-an-inhaled-potent-sars-cov-2-neutralizing-human-monoclonal-antibody-in-hamsters
#32
JOURNAL ARTICLE
Michael S Piepenbrink, Jun-Gyu Park, Fatai S Oladunni, Ashlesha Deshpande, Madhubanti Basu, Sanghita Sarkar, Andreas Loos, Jennifer Woo, Phillip Lovalenti, Derek Sloan, Chengjin Ye, Kevin Chiem, Christopher W Bates, Reuben E Burch, Nathaniel B Erdmann, Paul A Goepfert, Vu L Truong, Mark R Walter, Luis Martinez-Sobrido, James J Kobie
SARS-CoV-2 infection results in viral burden in the respiratory tract, enabling transmission and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody was derived from an IgM memory B cell of a COVID-19 patient, has high affinity for the Spike protein Receptor Binding Domain, neutralizes SARS-CoV-2 and exhibits in vivo prophylactic and therapeutic activity in hamsters when delivered intraperitoneally, reducing upper and lower respiratory viral burden and lung pathology. Inhalation of nebulized 1212C2 at levels as low as 0...
February 25, 2021: Cell reports medicine
https://read.qxmd.com/read/33643507/histologic-transformation-in-an-untreated-waldenstrom-s-macroglobulinemia-after-14-years-case-report-and-review-of-the-literature
#33
Elizabeth B Elimimian, Nadeem Bilani, Maria J Diacovo, Skirmante Sirvaitis, Chieh Lin Fu
Waldenstrom's macroglobulinemia (WM) is an indolent B-cell non-Hodgkin lymphoma characterized by lymphoplasmacytic histology in the bone marrow with monoclonal IgM. Median survival can be in excess of 10 years. The 5-year cumulative incidence of death is low at about 10%. One-third of all-cause specific mortality is due to the lymphoma for which histologic transformation (HT) is rare. Here we present a case of a 60-year-old man with longstanding untreated WM, presenting with minimally symptomatic transformation to diffuse large B-cell lymphoma (DLBCL), with an accompanying review of the literature...
February 2021: Journal of Hematology (Brossard, Quebec)
https://read.qxmd.com/read/33563895/mass-spectrometry-for-the-evaluation-of-monoclonal-proteins-in-multiple-myeloma-and-related-disorders-an-international-myeloma-working-group-mass-spectrometry-committee-report
#34
JOURNAL ARTICLE
David L Murray, Noemi Puig, Sigurdur Kristinsson, Saad Z Usmani, Angela Dispenzieri, Giada Bianchi, Shaji Kumar, Wee Joo Chng, Roman Hajek, Bruno Paiva, Anders Waage, S Vincent Rajkumar, Brian Durie
Plasma cell disorders (PCDs) are identified in the clinical lab by detecting the monoclonal immunoglobulin (M-protein) which they produce. Traditionally, serum protein electrophoresis methods have been utilized to detect and isotype M-proteins. Increasing demands to detect low-level disease and new therapeutic monoclonal immunoglobulin treatments have stretched the electrophoretic methods to their analytical limits. Newer techniques based on mass spectrometry (MS) are emerging which have improved clinical and analytical performance...
February 1, 2021: Blood Cancer Journal
https://read.qxmd.com/read/32538998/flow-cytometry-as-an-auxiliary-in-the-diagnosis-of-primary-humoral-immunodeficiencies
#35
JOURNAL ARTICLE
Leopoldo Santos-Argumedo, Laura Berrón-Ruiz, Gabriela López-Herrera, Nidia Carolina Moreno-Corona
Background: Antibody deficiencies encompass a wide spectrum of pathologies and constitute approximately 50 % of primary immunodeficiencies; with cytometry, it is possible to evaluate the immune status rapidly, effectively and at low cost. Objective: To assess, by means of flow cytometry, the cells of patients with three types of primary humoral immunodeficiencies. Method: Using flow cytometry, blood samples from patients and healthy subjects were analyzed with different monoclonal antibodies...
2020: Gaceta Médica de México
https://read.qxmd.com/read/32465116/better-abo-antibody-detection-tools-to-facilitate-abo-incompatible-transplant-risk-assessment
#36
JOURNAL ARTICLE
A Halpin, M Sosniuk, J Pearcey, B Motyka, S Maier, T L Lowary, C W Cairo, L J West
PURPOSE: Accurate characterization of ABO-Ab is critical to assess impact in ABOi transplantation. The current ABO-Ab detection method using erythrocyte agglutination is limited by lack of ABO-subtype specificity, imprecise ABO-Ab isotype differentiation, and poor reproducibility. We previously developed an ABO-glycan microarray to address these limitations. Our aim here was to create a solid phase bead assay for ABO-Ab analysis. METHODS: ABO A- and B-subtype antigens (I,II,III,IV,V,VI) were coupled to Luminex beads and quantified using monoclonal ABO-Ab...
April 2020: Journal of Heart and Lung Transplantation
https://read.qxmd.com/read/32296413/serum-free-light-chains-in-common-variable-immunodeficiency-disorders-role-in-differential-diagnosis-and-association-with-clinical-phenotype
#37
JOURNAL ARTICLE
Riccardo Scarpa, Federica Pulvirenti, Antonio Pecoraro, Alessandra Vultaggio, Carolina Marasco, Roberto Ria, Sara Altinier, Nicolò Compagno, Davide Firinu, Mario Plebani, Marco De Carli, Andrea Matucci, Fabrizio Vianello, Angelo Vacca, Giuseppe Spadaro, Isabella Quinti, Carlo Agostini, Cinzia Milito, Francesco Cinetto
We report on an observational, multicenter study of 345 adult CVID patients, designed to assess the diagnostic value and the clinical association of serum free light chain (sFLC) pattern in Common Variable Immunodeficiency disorders (CVID). Sixty CVID patients were tested twice in order to assess intraindividual variability of sFLC. As control groups we included 138 patients affected by undefined primary antibody defects (UAD), lymphoproliferative diseases (LPDs), and secondary antibody deficiencies not related to hematological malignancies (SID)...
2020: Frontiers in Immunology
https://read.qxmd.com/read/32269210/rituximab-use-and-hypogammaglobulinemia
#38
JOURNAL ARTICLE
Eaman Alhassan, Justina Johnson, Rasha Nakity, Hajra Zehra Shah
BACKGROUND Rituximab is a genetically engineered chimeric (murine-human) monoclonal antibody (mAb) directed against CD20 antigen on the surface of B cells. Commonly reported adverse effects are chills and fevers, which are usually associated with the first infusion. Recent studies have shown an association between rituximab use and low immunoglobulin (Ig) level due to a reduction in plasma cell precursors, which leads to an increased risk of infections with the use of rituximab. CASE REPORT We present a case of hypogammaglobulinemia associated with rituximab use in a patient with Granulomatosis with Polyangiitis (GPA)...
April 9, 2020: American Journal of Case Reports
https://read.qxmd.com/read/31917267/post-rituximab-immunoglobulin-m-igm-hypogammaglobulinemia
#39
REVIEW
Khalaf Kridin, A Razzaque Ahmed
Rituximab is a B cell depleting monoclonal antibody that targets the B cell-specific cell surface antigen CD20 and is currently used to treat several autoimmune diseases. The elimination of mature CD20-positive B lymphocytes committed to differentiate into autoantibody-producing plasma cells is considered to be the major effect of rituximab, that makes it a beneficial biological agent in treating autoimmune diseases. Hypogammaglobulinemia has been reported after rituximab therapy in patients with lymphoma and rheumatoid arthritis...
March 2020: Autoimmunity Reviews
https://read.qxmd.com/read/31858758/clinical-laboratory-and-bone-marrow-findings-of-31-patients-with-waldenstr%C3%A3-m-macroglobulinemia
#40
JOURNAL ARTICLE
Ari Ahn, Chan Jeoung Park, Young Uk Cho, Seongsoo Jang, Eul Ju Seo, Jung Hee Lee, Dok Hyun Yoon, Cheolwon Suh
BACKGROUND: Waldenström macroglobulinemia (WM) is a subset of lymphoplasmacytic lymphoma (LPL) with bone marrow (BM) involvement and an IgM monoclonal gammopathy of any level. We aimed to identify the clinical, laboratory, and BM findings of patients with WM and to evaluate the usefulness of CD154 for the diagnosis and prognosis of WM. METHODS: We reviewed the medical records and BM studies and/or flow cytometric immunotyping of 31 patients with untreated WM. Semiquantitative immunohistochemistry (CD20, CD138, tryptase, and CD154) of BM was performed...
May 2020: Annals of Laboratory Medicine
keyword
keyword
76214
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.